Coverage
-
April 19, 2018
Bio-Pharm Inc. must face a suit accusing the company of reneging on a drug supply agreement and holding generic medication "hostage" in order to gain a larger share of the profits than originally agreed upon, an Illinois federal judge ruled Thursday.
2 other articles on this case.
View all »